

Attorney Docket No. 5218-39B  
In re: Anagnostou et al.  
Serial No.: 09/525,797  
Filed: March 15, 2000  
Page 2

### **Listing of Claims**

The following list of claims will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

12. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to initial administration of a chemotherapeutic agent, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said chemotherapeutic agent.

13-14. (Canceled)

15. (Currently Amended) A method according to claim 12, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin and mitomycin.

16-18. (Canceled)

19. (Currently Amended) A method according to claim 15, wherein said chemotherapeutic agent cisplatin is administered intravenously.

20. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered intravenously.

21. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to initial administration of cisplatin ~~a chemotherapeutic agent~~;

wherein said erythropoietin is administered in an amount of from about 750 Units per kilogram to about 2,000 Units per kilogram.

Attorney Docket No. 5218-39B  
In re: Anagnostou et al.  
Serial No.: 09/525,797  
Filed: March 15, 2000  
Page 3

22- 23. (Canceled)

24. (Currently Amended) A method according to claim 21 [[23]], wherein said cisplatin is administered intravenously.

25. (Previously Presented) A method according to claim 21, wherein said erythropoietin is administered intravenously.

26. (Currently Amended) A method according to claim 15, wherein said chemotherapeutic agent cisplatin is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

27-30. (Canceled)

31. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a cerebellar hemangioblastoma.

32. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a ductal carcinoma of the breast.

33. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a squamous cell cancer of the larynx.

34. (Currently Amended) A method of treating a solid vascularized tumor according to claim 12 [[1]], wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.

Attorney Docket No. 5218-39B  
In re: Anagnostou et al.  
Serial No.: 09/525,797  
Filed: March 15, 2000  
Page 4

35. (Previously Presented) A method of treating a solid vascularized tumor according to claim 21, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.